CD19 and acute lymphoblastic leukemia: The clinical efficacy of CD19 targeted CAR T cells led to two US Food and Drug Administration (FDA)-approvals in 2017, Kymriah in acute B cell lymphoblastic leukaemia (B-ALL) and Yescarta in diffuse large B-cell lymphoma (DLBCL) [4,5].